Chi Podcasts

Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California Dr. Jennifer Dien Bard shares her insights into what the biggest challenges and opportunities are in implementing molecular point-of-care testing for infectious disease diagnostics, and rapid genetic and phenotypic susceptibility testing. Jennifer will be speaking at Molecular Diagnostics for Infectious Disease and co-instructing a short course on Rapid Diagnostics for Antimicrobial Resistance at the Next Generation Dx Summit August 20 to 24, 2018 in Washington, DC. For more information please visit http://www.NextGenerationDX.com/Infectious-Disease-Diagnostics/ and http://www.NextGenerationDX.com/SC-6/

Prof. Massimo Cristofanilli shares his perspective on the future of liquid biopsy, the complementary purposes of CTC and cfDNA technologies, and when one should expect clinical utility of liquid biopsies. For more information, please visit http://www.NextGenerationDx.com/Circulating-Tumor-Cells/

Dr. Bruce Quinn talks about his latest work, challenges to implementing precision medicine, advice for overcoming them and tips for integrating into the clinic. He discusses exciting new developments that are emerging and where the field is heading. For more information, please visit http://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics/

Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community and more. For more information, please visit http://www.NextGenerationDX.com/Reimbursement-Diagnostics/ and http://www.NextGenerationDX.com/Precision-Medicine/

Paul Yager of University of Washington speaks to CHI on May 4, 2018. Dr. Paul Yager from the University of Washington. Dr. Yager will be speaking at the Enabling Point-of-Care Diagnostics and the Microfluidics and Lab-on-a-Chip Devices for point-of-care testing tracks at the upcoming Next Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, DC. Topics include his lab’s success in developing NAAT testing, obstacles to developing low cost diagnostics and advice for those looking to get into the field. For more information, please visit http://www.NextGenerationDX.com/Point-of-Care-Diagnostics/ and http://www.NextGenerationDX.com/Microfluidics/

Suman Bose of Massachusetts Institute of Technology speaks to CHI on May 3, 2018. Dr. Bose will be speaking at the Single Cell Analysis and at the Microfluidics and Lab-on-a-Chip Devises for point of care testing tracks at the upcoming Next Generation Diagnostics Summit that is held from August 20th through the 24th in Washington, D.C. Topics include motivation for single cells analysis, overcoming challenges and outlooks for the Summit. For more information, please visit http://www.NextGenerationDX.com/Microfluidics/ and http://www.NextGenerationDX.com/Single-Cell-Analysis/

Dr. James Hendler of Rensselaer Polytechnic Institute speaks to Cambridge Healthtech Institute on April 13, 2018. He will be a presenter during the Machine Learning and Data Visualization & Exploration Tools tracks at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) What led you to work on precision wellness as a part of your research on artificial intelligence, agent-based computing, high-performance processing, and the Semantic Web (of which you’re one of the originators)? 2) Let’s discuss emerging technologies from machine learning and artificial intelligence. What applications do they have on healthcare? What’s their potential impact? 3) What role might AI-driven technologies have in enhancing data visualization in genomics, drug discovery, or clinical development? For more information, please visit http://www.Bio-ITWorldExpo.com/

Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Let’s touch upon your gene discovery work. What determines the disease genes and conditions you study, with an eye on clinical impact? 2) How does research on rare and orphan disease enhance our understanding of medicine overall? 3) While you zoom in on rare diseases for the sake of broader knowledge, you also look broadly or globally to answer local questions, liaising between academia and industry, and partnering with clinicians with a shared goal of enhancing patient care. What do both the research and clinical sides need to contribute to the process, and what challenges still need to be

Dr. Nirmala Shenoy of Rochester Institute of Technology speaks to Cambridge Healthtech Institute on April 6, 2018. She will be a presenter during the Data Transfer track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Why have you focused your recent research on Internet architectures and protocols and computational challenges faced by network protocols? 2) Let’s address scalability. How will supporting high-speed data transfers in large or across multiple networks, or provisioning for larger amounts of high-speed data, impact the security of scientific data? 3) How have Internet and routing protocols evolved in the last decade, and what further changes do you foresee in coming years? For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Transfer/

Tim Sweeney spoke to CHI to discuss his company’s work in using host response to diagnose and risk stratify patients with sepsis infections. He also discusses current shortcomings sepsis diagnostics, as well as what he sees as barriers in implementing rapid diagnostics and how the field is moving forward to overcome these barriers. For more information, please visit http://www.MolecularDXEurope.com/Infectious-Disease-Dx/

Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to unlock new mechanisms and pathways. Dr. Cho is speaking at the Blood-Brain Barrier conference, part of World Preclinical Congress, taking place June 18-21, 2018 in Boston, MA. For more details, please visit: http://www.worldpreclinicalcongress.com

Dr. Andrew Bradbury talks about his latest work using NGS to build a single donor library, and shares lessons he has learned along the way. He describes the unique approach they are using at Specifica and outlines tips for creating antibody libraries with improved diversity and developability. For more information, please visit http://www.PEGSummit.com/Phage-Display/

Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics. For more information, please visit http://www.MolecularDXEurope.com/MDXE_Content.aspx?id=190671

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward. For more information please visit http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/

Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Technologies for Cell-Free DNA Analysis conference, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal. For more information, please visit http://www.MolecularDXEurope.com/Cell-Free-DNA-Technology/

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for: · Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health · Developing novel endpoints based on an individual’s day-to-day experience · Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points · Optimizing study recruitment and protocol compliance through digital channels For more information, please visit http://www.Bio-ITWorld.com

Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for April 30 - May 4, 2018 in Boston, with the antibodies program set for May 2-3. For more information, please visit http://www.PEGSummit.com/Engineering-Antibodies

Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is speaking at the Advances in prenatal Molecular Diagnostics meeting, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal For more information, please visit http://www.MolecularDXEurope.com/Prenatal-Dx/

Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change. For more information, please visit http://www.MolecularDXEurope.com/mdxe_content.aspx?id=190671

Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays for Biologics at the PEGS Summit this May 3-4 in Boston, MA! For more information, please visit http://www.PEGSummit.com/Bioassays-Conference/